spacer
home > pmps > Spring 2016
PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

pmps
Spring 2016

   
Text
PDF
Industry Insight 
Industry Insight

PMPS Industry Advisor Robert Harris discusses today's global supply chain logistics challenges in pharma, and how biologics have come to take a greater share in the pharmaceuticals market.
 
view
download pdf
bullet
Drug Delivery 
Pen and Auto-Injector Production

Springing to Life


Dr Tolga Goren of BAUMANN Springs investigates the growing role of springs in medical pens and auto-injectors. What are the development challenges that face a manufacturer of this small, yet essential, part of such an important device?
 
view
download pdf
Parenteral Delivery Trends

Packaging Patient Needs

As demand for injection devices increases, so does the number of new solution providers in this field, states Rasmus Renstad at SHL Group. He shares his advice on how to find your perfect partner, and how to give patients exactly what they want.
 
view
download pdf
bullet
Labelling 
Medical Device Identification

Labelled as Safe


The complexities of implementing the FDA’s unique device identifier system into medical device packaging can leave affected companies feeling daunted. Kevin Grygiel at PRISYM ID explains the advantages of label lifecycle management capability.
 
view
download pdf
bullet
Anti-Counterfeiting
Counterfeits Update

Time for Action


Aegate’s Graham Smith reports on the Falsified Medicines Directive and the recently published Delegated Regulation, and considers how implementation will work in practice at each point in the pharma supply chain.
 
view
download pdf
Serialisation Requirements

Mark My Words


What coding and marking options are available to manufacturers to help fight counterfeiters? Richard Nemesi at Videojet Technologies outlines a number of solutions that can enhance traceability, which in turn will protect product authenticity, consumer safety and brand reputation.
 
view
download pdf
bullet
SUPPLY CHAIN MANAGEMENT & LOGISTICS
Cold Chain Management

Logistical Nightmare


Mark Sawicki at Cryoport advocates the use of controlled facilities, dry vapour packaging and tracking to take control of the transport of temperature-sensitive pharmaceuticals for clinical trials.


 
view
download pdf
Pharma Air Freight

Better Together

Can pharma companies do more to enhance the supply chain? Pelican BioThermal’s Ira Smith believes that greater collaboration between shippers and 3PLs – and, ultimately, formation of a global regulatory standardisation – is key to success.
 
view
download pdf
Q&A: Industry Efficiency

Collaboration is King


Mark Blanchard at BioPhorum Operations Group describes to PMPS how stakeholders throughout the pharma supply chain can work together better – by sharing knowledge, rather than adapting an “us versus them” mentality.
 
view
download pdf
FlyPharma Event Preview

Pharma Takes Flight


Putting the spotlight on the benefits of collaboration between pharma shippers and logistics service providers, the FlyPharma Conference 2016 offers a great opportunity to network with like-minded industry decision-makers and gain insight into making the pharma supply chain stronger.
 
view
bullet
CLINICAL TRIAL SUPPLIES & LOGISTICS
Device Studies

Responsive Performance

It can be both difficult and expensive for researchers to manage medical device clinical trials. However, Grant Dietrich at Cenduit explains that with the right interactive response technology, it could be made cheaper and more efficient.
 
view
download pdf
bullet
MANUFACTURING & PROCESSING
Supply Chain Operations

Waste Not, Want Not


Could Big Pharma’s resistance to change restrict manufacturers’ ability to apply a new, flexible approach to efficiency? Hugh Williams from Hughenden Consulting challenges the industry to be more open to an integrated, end-to-end supply chain.
 
view
download pdf
Continuous Manufacturing

Keep it Moving


Peter Webster at PCI Pharma Services and Duncan Betteley at S3 Process Ltd offer their views on continuous manufacturing methods as an alternative to batch production – and warn that pharma’s hesitancy to consider this approach causes it to fall behind the levels of progression other industries are experiencing.
 
view
download pdf
bullet
COOL CHAIN
Safe Drug Storage

Kept in Check

Legislation protecting medical products against temperature increases during storage is strict, but necessary to ensure drug integrity. Air conditioning equipment has advanced considerably, but what do you do when things go wrong? Carl Webb at Andrews Sykes Specialist Hire reports.
 
view
download pdf
bullet
The End of the line
End of the Line

Wait and See


Outlining the implications of a possible UK ‘Brexit’ from the EU for pharma, Robert Harris wonders what might happen to the relationship between the EMA and the MHRA, as well as other healthcare bodies.
 
view
download pdf
   
spacer
Edited by
Randice Altschul
Chief Executive Officer at Pop Test and Palisades Therapeutics

Published quarterly in
February, May,
August, and November

News and Press Releases

PredictImmune announce issuance of new patent in the US in support of commercialisation

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk. This follows successful grants across the company’s first family of IP in the UK and Europe in October 2018 and Canada in January this year.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement